Becton, Dickinson and (BDX) EVP David Sells $160K of Stock

On June 24, 2026, Garrison Michael David, the Executive Vice President & President of Medical Essentials and BioPharma at Becton, Dickinson and Company, sold 1,100 shares. The shares were sold at an average price of $145.66 each, amounting to a total transaction value of $160,226. This move was part of a pre-planned trading program under Rule 10b5-1.

Insider Buying and Selling at Becton, Dickinson and Company

Garrison Michael David's recent sale of 1,100 shares on June 24 was not his first transaction this month. Earlier, on June 10, he sold another 1,100 shares at $151.48 per share. Meanwhile, Thomas Polen Jr., Chairman, CEO, and President of Becton Dickinson, executed multiple transactions on June 1. He sold 17,445 shares at $146.15 each and 2,764 shares at $146.35, while also buying 20,209 shares at $126.16.

Becton, Dickinson and Company Stock Down 16.3%

Shares of Becton Dickinson (NYSE:BDX) traded near $147.77 on Thursday. The company has a market capitalization of approximately $38.77 billion, with a P/E ratio of 24.56 and a forward P/E of 10.51. Its beta stands at 0.278, indicating lower volatility compared to the market. The stock's 52-week range is between $127.59 and $187.35, and its 50-day moving average is $148.96, while the 200-day moving average is $154.07.

Analysts Set New Price Targets

On May 11, 2026, Barclays maintained its 'buy' rating for Becton Dickinson with a price target of $204. Argus Research also maintained a 'buy' rating, setting a target of $180 on March 23. Other firms like Wells Fargo and TD Cowen have a 'hold' rating with targets of $161 and $163, respectively. The consensus recommendation is a 'buy,' with an average target price of $180.69 based on 13 analyst opinions.

About Becton Dickinson

Becton, Dickinson and Company, headquartered in Franklin Lakes, New Jersey, is a global medical technology firm. It designs, manufactures, and sells a wide range of medical supplies, devices, laboratory equipment, and diagnostic products. The company's offerings are used in healthcare institutions, clinical laboratories, and the pharmaceutical industry. Founded in 1897, Becton Dickinson employs about 60,000 people and operates through segments like Medical Essentials and BioPharma Systems. Its CEO is Thomas E. Polen Jr.

Bottom Line

The recent insider sale by Garrison Michael David is part of a planned trading strategy and not uncommon among executives. Investors often track such moves for insights into company leadership's confidence. While insiders selling shares can raise eyebrows, it doesn't necessarily signal a lack of confidence in the company. Becton Dickinson remains a significant player in the healthcare sector, and analysts continue to show confidence with positive ratings and price targets.